Skip to content
Accessibility help
Search NICE…
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Deferred
Awaiting development
Topic prioritisation
Filter (1 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (1)
Type
Type
Guidance (94)
Quality standard (2)
Guidance programme
Guidance programme
Clinical guidelines (7)
Diagnostics guidance (2)
Health technology evaluations (4)
HealthTech guidance (1)
Highly specialised technologies guidance (2)
Interventional procedures guidance (2)
Medical technologies guidance (1)
NICE guidelines (8)
Technology appraisal guidance (77)
Apply filters
Showing 1 to 96 of 96
Sort by
Title
Date
Apply sorting
Keyword or reference number: in
`Remove $Keyword or reference number: in filter`
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites
in
children 5 to 11 years [ID6510]
Technology appraisal guidance
26 August 2026
Abaloparatide for treating idiopathic or hypogonadal osteoporosis
in
men [ID4059]
Technology appraisal guidance
TBC
Aggressive behaviour
in
people receiving NHS or social care
Quality standard
28 January 2027
Aggressive behaviour
in
people receiving NHS or social care: prevention and management
NICE guideline
28 January 2027
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments
in
people 2 years and over [ID6570]
Technology appraisal guidance
TBC
Baloxavir marboxil for influenza prophylaxis
in
people aged 12 and over [ID3793]
Technology appraisal guidance
TBC
Baloxavir marboxil for reducing direct transmission of influenza A or B
in
people 5 to 64 years [ID6552]
Technology appraisal guidance
TBC
Baricitinib for treating severe or very severe alopecia areata
in
people 6 to 17 years [ID6541]
Technology appraisal guidance
TBC
Benralizumab to reduce exacerbations
in
moderate to very severe chronic obstructive pulmonary disease [ID1394]
Technology appraisal guidance
TBC
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen
in
people 5 to 17 years [ID6537]
Technology appraisal guidance
26 August 2026
Bevacizumab
in
combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]
Technology appraisal guidance
20 February 2019
Brensocatib for treating non-cystic fibrosis bronchiectasis
in
people 12 years and over [ID6448]
Technology appraisal guidance
TBC
Canagliflozin for treating chronic kidney disease
in
people with type 2 diabetes [ID1653]
Technology appraisal guidance
TBC
CaRi-Heart for predicting cardiac risk
in
adults with suspected coronary artery disease (CAD)
Health technology evaluation
2 December 2026
Catumaxomab for intraperitoneal treatment of malignant ascites
in
epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]
Technology appraisal guidance
30 September 2026
COLOFIT algorithm to guide colorectal cancer pathway referral
in
primary care: early value assessment
Health technology evaluation
TBC
Daprodustat for treating anaemia
in
people with chronic kidney disease [ID3987]
Technology appraisal guidance
TBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia
in
children and adults [ID1297]
Technology appraisal guidance
28 July 2021
Denecimig (Mim8) for preventing bleeding episodes
in
haemophilia A
in
people of any age [ID6400]
Technology appraisal guidance
24 February 2027
Depemokimab for treating severe eosinophilic asthma
in
people 12 years and over [ID6447]
Technology appraisal guidance
TBC
Dexmedetomidine for treating agitation associated with bipolar disorder
in
people 18 to 75 years [TSID10725]
Technology appraisal guidance
TBC
Diabetes
in
pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)
NICE guideline
12 August 2026
Digital technologies delivering CBT for insomnia
in
adults
Health technology evaluation
6 January 2027
Digital technologies to support smoking cessation
in
secondary care patients: early value assessment
Health technology evaluation
TBC
Donidalorsen for preventing recurrent attacks of hereditary angioedema
in
people 12 years and over [ID6457]
Technology appraisal guidance
18 June 2026
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency
in
people of any age [ID6484]
Highly specialised technology
TBC
Dupilumab for treating chronic spontaneous urticaria
in
people 12 years and over [ID4055]
Technology appraisal guidance
TBC
Durvalumab
in
combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]
Technology appraisal guidance
TBC
Elamipretide for treating Barth syndrome
in
people of any age [ID6545]
Technology appraisal guidance
TBC
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation
in
the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor
in
people aged 6 and over [TSID11847]
Technology appraisal guidance
TBC
Epilepsies
in
children, young people and adults
NICE guideline
TBC
Epilepsies
in
children, young people and adults (extraordinary review)
NICE guideline
TBC
Evolocumab for preventing major cardiovascular events
in
people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke [TSID11920]
Technology appraisal guidance
TBC
Fidrisertib for reducing heterotopic ossification caused by fibrodysplasia ossificans progressiva
in
people 5 years and over [ID6678]
Technology appraisal guidance
TBC
Gene expression profiling tests for estimating risk
in
newly diagnosed multiple myeloma
HealthTech guidance
TBC
Givinostat for treating Duchenne muscular dystrophy
in
people 6 years and over [ID6323]
Technology appraisal guidance
TBC
Govorestat for treating classic galactosemia
in
people 2 to 65 years [TSID12071]
Technology appraisal guidance
TBC
Heart valve disease presenting
in
adults: investigation and management - transcatheter aortic valve implantation (TAVI) to treat aortic stenosis (update)
NICE guideline
TBC
Icotrokinra for treating moderate to severe plaque psoriasis
in
people 12 years and over [ID6579]
Technology appraisal guidance
TBC
Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma
in
people 12 years and over [TSID12279]
Technology appraisal guidance
TBC
In
-situ normothermic regional perfusion of the abdomen for livers donated after controlled circulatory death
Interventional procedures guidance
19 November 2026
Inclacumab for preventing recurrent vaso-occlusive crises
in
sickle cell disease
in
people 16 years and over [ID6551]
Technology appraisal guidance
TBC
Insulin efsitora alfa for treating type 1 diabetes
in
people on multiple daily insulin injections [ID6498]
Technology appraisal guidance
TBC
Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy
in
people 2 years and over [ID6556]
Technology appraisal guidance
26 August 2026
Iptacopan for treating complement 3 glomerulopathy
in
people 12 to 18 years [ID6738]
Technology appraisal guidance
TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma
in
people who cannot have autologous stem cell transplant [ID2706]
Technology appraisal guidance
TBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures
in
epilepsy [ID1687]
Technology appraisal guidance
TBC
Lenacapavir for preventing HIV-1
in
people aged 16 years or older [ID6495]
Technology appraisal guidance
TBC
Leriglitazone for treating cerebral adrenoleukodystrophy
in
boys and men 2 years and over [ID3903]
Technology appraisal guidance
TBC
Leukocyte interleukin
in
combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]
Technology appraisal guidance
TBC
Low-dose atropine eye drops for treating myopia
in
people 3 to 14 years [ID6517]
Technology appraisal guidance
3 September 2026
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (
in
combination with bevacizumab) [ID44]
Technology appraisal guidance
TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (
in
combination with bevacizumab) [ID43]
Technology appraisal guidance
TBC
Lutetium-177 vipivotide tetraxetan
in
combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]
Technology appraisal guidance
TBC
Maralixibat for treating cholestatic pruritus
in
Alagille syndrome [ID3941]
Technology appraisal guidance
TBC
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer
in
the liver
Interventional procedures guidance
15 October 2026
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas
in
people 2 years and over with neurofibromatosis type 1 [ID6618]
Technology appraisal guidance
3 September 2026
Mozafancogene autotemcel for treating Fanconi anaemia
in
people 1 to 17 years [TSID12203]
Technology appraisal guidance
TBC
Nivolumab
in
combination for untreated advanced classical Hodgkin lymphoma
in
people 12 years and over [ID6690]
Technology appraisal guidance
TBC
Nivolumab with brentuximab vedotin for treating CD30-positive relapsed or refractory classical Hodgkin lymphoma after 1 treatment line
in
people 5 years and over [ID6691]
Technology appraisal guidance
TBC
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma
in
people 12 years and over [ID6475]
Technology appraisal guidance
TBC
Nogapendekin alfa inbakicept with intravesical BCG for non-muscle-invasive bladder cancer with carcinoma
in
situ that is unresponsive to BCG [ID6582]
Technology appraisal guidance
4 November 2026
Obeticholic acid for treating liver fibrosis
in
people with steatohepatitis [ID1645]
Technology appraisal guidance
TBC
Odevixibat for treating cholestasis and pruritus
in
Alagille Syndrome [ID6181]
Technology appraisal guidance
TBC
Opicapone for adjunctive treatment of motor signs and symptoms
in
Parkinson's disease [TSID11941]
Technology appraisal guidance
TBC
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity
in
people 6 years and over with spinal cord injury or spina bifida [ID5089]
Technology appraisal guidance
TBC
Palforzia for treating peanut allergy
in
children aged 1 to 3 [ID6144]
Technology appraisal guidance
TBC
Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis
in
people 12 years and over [ID6489]
Technology appraisal guidance
18 June 2026
Perioperative care
in
adults
Quality standard
1 July 2026
Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis
in
people 12 years and over [ID6497]
Technology appraisal guidance
TBC
Repotrectinib for treating NTRK fusion-positive advanced solid tumours
in
people 12 years and over [TSID12147]
Technology appraisal guidance
TBC
Ribociclib
in
combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer
in
premenopausal women [ID1307]
Technology appraisal guidance
TBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia
in
people aged 12 and over [ID6395]
Technology appraisal guidance
TBC
Rivogenlecleucel for treating haematological cancers
in
children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Technology appraisal guidance
TBC
Rivogenlecleucel for treating haematological non-malignant diseases
in
children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Technology appraisal guidance
TBC
Rocatinlimab for treating moderate to severe atopic dermatitis
in
people 12 years and over [ID6565]
Technology appraisal guidance
TBC
Sebetralstat for treating acute attacks of hereditary angioedema
in
people aged 12 and over [ID6284]
Technology appraisal guidance
TBC
Secukinumab for treating giant cell arteritis
in
people 50 years and over [ID6563]
Technology appraisal guidance
TBC
Selpercatinib for treating RET fusion-positive advanced solid tumours
in
people aged 12 and over with no other treatment options [ID6273]
Technology appraisal guidance
TBC
Semaglutide for reducing the risk of major adverse cardiovascular events
in
people with cardiovascular disease and overweight or obesity [ID6441]
Technology appraisal guidance
7 May 2026
Setmelanotide for treating acquired hypothalamic obesity
in
people 4 years and over [ID6542]
Technology appraisal guidance
10 February 2027
Setmelanotide for treating obesity and hyperphagia
in
Bardet-Biedl syndrome (review of HST31) [ID6598]
Highly specialised technology
19 August 2026
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex
in
people 6 years and older (review of TA972) [ID6440]
Technology appraisal guidance
TBC
Sirolimus-eluting collagen implant for creating vascular access for haemodialysis
in
end-stage kidney disease [TSID9147]
Technology appraisal guidance
TBC
Soticlestat for treating seizures associated with Dravet syndrome
in
people 2 years and over [TSID12091]
Technology appraisal guidance
TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome
in
people 2 years and over [TSID10632]
Technology appraisal guidance
TBC
Spesolimab for preventing generalised pustular psoriasis flares
in
people 12 years and over [TSID12086]
Technology appraisal guidance
TBC
Suspected sepsis
in
pregnancy: recognition, diagnosis and early management
NICE guideline
17 February 2027
Suspected sepsis
in
under 16s: recognition, diagnosis and early management
NICE guideline
17 February 2027
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer
in
postmenopausal women [ID1401]
Technology appraisal guidance
TBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes
in
people 8 years and over with stage 2 type 1 diabetes [ID6259]
Technology appraisal guidance
TBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex
in
people 6 years and over [ID6391]
Technology appraisal guidance
TBC
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation
in
people 6 months and over [ID6557]
Technology appraisal guidance
TBC
Venous thromboembolism
in
over 16s : aspirin following orthopaedic surgery (update)
NICE guideline
TBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery
in
people 12 years and over [ID6407]
Technology appraisal guidance
29 April 2026
Vosoritide for treating achondroplasia
in
people 4 months and over [ID6488]
Technology appraisal guidance
TBC
Current page
1
Page
1
of
1
Results per page
10
25
50
All
Back to top